| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-04-20 | UCHL1 inhibitors | Mission Therapeutics (UK) | Cancer - Oncology | ||
| 2015-04-20 | SAGE-547 | super-refractory status epilepticus (SRSE) | 3 | Sage Therapeutics (USA - MA) | CNS diseases - Neurological diseases |
| 2015-04-20 | AV-380 | cancer cachexia |
preclinical | Aveo Oncology (USA - MA) | Cancer - Oncology |
| 2015-04-20 | avelumab (MSB0010718C) | stage IIIb/IV non-small cell lung cancer
|
3 | Pfizer (USA - NY) Merck KGaA (Germany) | Cancer - Oncology |
| 2015-04-20 | Spinal Muscular Atrophy (SMA) program including motor neuron 2 (SMN2) gene splicing modifier (RG7800) | spinal muscular atrophy |
1b - 2a | PTC Therapeutics (USA - NJ) SMA Foundation (USA) Roche (Switzerland) | Neuromuscular diseases - Rare diseases - Genetic diseases |
| 2015-04-20 | Opdivo® (nivolumab)+Yervoy® (ipilimumab) | previously untreated advanced melanoma | 2 | BMS (USA - NY) | Cancer - Oncology |
| 2015-04-19 | avapritinib (BLU-285) | gastrointestinal stromal tumors (GIST) |
preclinical | Blueprint Medicines (USA - MA) | Cancer - Oncology |
| 2015-04-17 | PQR309 | advanced solid tumors |
1 | Piqur Therapeutics (Switzerland) | Cancer - Oncology |
| 2015-04-17 | Vonvendi®/Veyvondi®- BAX111 (recombinant von Willebrand Factor) | Von Willebrand Disease | 3 | Baxter (USA - IL) | Hematological diseases - Genetic diseases - Rare diseases |
| 2015-04-17 | Cingal® (cross-linked sodium hyaluronate combined with triamcinolone hexacetonide) | symptomatic relief of osteoarthritis (OA) of the knee |
3 | Anika Therapeutics (USA – MA) | Rheumatic diseases |
| 2015-04-17 | galunisertib and nivolumab | solid tumors, non-small cell lung cancer, hepatocellular carcinoma, glioblastoma | 1-2 | Eli Lilly (USA - IN) BMS (USA - NY) | Cancer - Oncology |
| 2015-04-17 | AZD9291 | (EGFRm+), advanced non-small cell lung cancer (NSCLC) |
1-2 | AstraZeneca (UK) | Cancer - Oncology |
| 2015-04-17 | brigatinib (AP26113) | anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer (NSCLC) | 1-2 | Ariad Pharmaceuticals (USA - MA) | Cancer - Oncology |
| 2015-04-16 | miR-31-3p biomarker | advanced stage non-small cell lung cancer (NSCLC) | Integragen (France) | Cancer - Oncology | |
| 2015-04-16 | Otezla® (apremilast) | Behçet's disease | 2 | Celgene (USA - NJ) | Rare diseases - Inflammatory diseases |
| 2015-04-16 | ponesimod | relapsing multiple sclerosis | 3 | Actelion (Switzerland) | Neurodegenerative diseases |
| 2015-04-16 | ponesimod | chronic graft-versus-host disease (GHVD) | 2 | Actelion (Switzerland) | Transplantation - Immunological diseases |
| 2015-04-16 | demcizumab | non-small cell lung cancer (NSCLC) | 1b | OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2015-04-16 | ACT-334441 | systemic lupus erythematosus | 1-2 | Actelion (Switzerland) | Autoimmune diseases |
| 2015-04-15 | KHK6640 | Alzheimer\'s disease | 1 | OncoTherapy Science (Japan) Kyowa Hakko Kirin (Japan) | Neurodegenerative diseases |
